Five Chinese firms announced yesterday that they had postponed their initial public offerings (IPOs) after China’s stock regulator said overnight it would strengthen its supervision of new listings.
The announcements follow a similar statement by drugmaker Aosaikang (奧賽康) on Friday which sources told reporters was due to regulatory pressure, although the China Securities Regulatory Commission (CSRC) denied it.
The five companies are NetPosa Technologies Ltd (東方網力), Hebei Huijin Electromechanical Co Ltd (河北匯金機電), Nsfocus Information Technology Co Ltd (綠盟科技), Beijing Forever Technology Co Ltd (恆華科技) and Ciming Health Checkup Management Group Co Ltd (慈銘體檢).
“In line with the CSRC statement on Jan. 12, the issuer and lead underwriters have decided to adjust the timetable for the company’s planned share issuance,” Ciming Health said in its announcement, without giving a new time frame for the issue.
The other four firms issued similar statements.
The CSRC said on Sunday that any companies which set their IPO price-to-earnings (PE) ratios higher than the ratios of industrial peers in the secondary market must publish repeated risk warnings before they open subscriptions to retail investors, a move that will effectively reduce IPO prices and slow the progress of new issues.
Aosaikang appeared to be a retroactive violator of this rule by putting its price-to-earnings ratio at 67, versus 55 for its industry peers.
Analysts said regulators were also likely bothered by the company’s plans to dedicate most of the IPO to letting major stakeholders sell off their existing shares, instead of issuing new ones.
The six suspensions comprise around one-fifth of all the companies that have filed to list in Shanghai and Shenzhen since the IPO gates were lowered early this month.
This marks an inauspicious beginning to the resumption of IPOs in China, which regulators hoped would help nearly 750 companies, stuck in the queue since listings were frozen in late 2012 find sources of fresh funds outside the already overburdened banking system.
Ernst & Young has estimated these firms will raise around 200 billion yuan (US$33.05 billion) on the Chinese bourses this year.
Initial signs were promising, with the first two IPOs attracting massive investor interest during the subscription process.
In wider terms, the suspensions mark a setback for reformers in Beijing who have committed to giving markets a “decisive” role in the next phase of Chinese economic development.
The aborted listings highlight the challenges the government faces in liberalizing a market still dominated by companies unused to the requirements of transparent corporate governance.
The CSRC has said it will loosen its grip on the IPO process, changing its current approval-based system — where it decides who gets to list and who does not — to a registration-based system similar to the one used in the US.
This would diminish opportunities for corruption, but it also would limit regulators’ ability to protect China’s army of retail stock investors from unethical company managers.
China shares underperformed most of Asia yesterday, taking no cheer from the postponement of those new listings.
The CSI300 of the largest Shanghai and Shenzhen A-share listings ended down 0.5 percent at 2,193.7 points, its lowest closing level since the end of July last year.
The Shanghai Composite Index slipped 0.2 percent in lackluster volume.
The ChiNext Composite Index of mainly startups in technology and other nascent industries listed in Shenzhen outperformed, rising 0.7 percent.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained